PATIENT SAVINGS
Print out a Welchol Savings Card for your eligible patients today!

Welchol Clinical Studies

PRINT SAVINGS CARD NOW

LDL-C and A1C reductions

In the appropriate patient, as an adjunct to diet and exercise, Welchol is the only bile acid sequestrant FDA-approved to provide both LDL-C and A1C reductions in adults with primary hyperlipidemia and T2DM. See how Welchol compares to atorvastatin, simvastatin, and metformin.

WELCHOL + ATORVASTATIN 10 mg:

Lowered LDL-C and raised HDL-C without statin titration
Adding Welchol to atorvastatin 10 mg significantly lowered LDL-C, comparable to atorvastatin 80 mg1,2

Welchol® LDL-C levels Welchol® LDL-C levels Welchol® HDL-C levels Welchol® HDL-C levels

  • The most common adverse events were flatulence (26%) and constipation (21%) in the Welchol + atorvastatin 10 mg group and
    infection (24%) in the Welchol 3.8 g alone group2
  • T2DM was not an inclusion criterion for this study
  • Reduction in HDL-C was a secondary endpoint in this study and Welchol is not indicated to raise HDL-C

Welchol (N=16) vs placebo (N=19).

Hunninghake D, et al. Atherosclerosis. 2001. Please see study design B.

As an add-on,
Welchol + atorvastatin 10 mg lowered APO B by 38%1,2

Welchol® APO B Levels Welchol® APO B Levels

Welchol is not indicated to lower APO B. APO B was a secondary endpoint in this study.

  • T2DM was not an inclusion criterion for this study
  • The most common reported adverse events were flatulence (26%) and constipation (21%) in the Welchol + atorvastatin 10 mg group and infection (24%) in the Welchol 3.8 g alone group2

ǁWelchol (N=16) vs placebo (N=19).

At baseline, 68% of patients had LDL cholesterol levels <190 mg/dl, and 32% of patients had LDL cholesterol levels >190 mg/dl.2

Hunninghake D, et al. Atherosclerosis. 2001. Please see study design B.

Study Design B (Hunninghake D, Atherosclerosis. 2001) Results from a randomized, double-blind, placebo-controlled, 4-week study of 94 randomized patients with moderate hypercholesterolemia (LDL-C ≥160 mg/dL, TG ≤300 mg/dL) and LDL-C levels ranging from 156-236 mg/dL. Patients were assigned to 1 of 5 treatment groups: placebo, Welchol 3.8 g/day, atorvastatin 10 mg/day, atorvastatin 80 mg/day, or atorvastatin 10 mg/day + Welchol 3.8 g/day.1,2

Hypercholesterolemia is now referred to as primary hyperlipidemia.

Please see Important Safety Information about Welchol below.
Welchol Savings for Your Patients

Based on a $0 co-pay for a 90-day supply or a $10 co-pay for a 30-day supply. Restrictions apply based on eligibility. See Terms & Conditions below.

PRINT SAVINGS
CARD NOW
Welchol® (colesevelam HCI) A1C Treatment Forms

Based on a $0 co-pay for a 90-day supply or a $10 co-pay for a 30-day supply. Restrictions apply based on eligibility. See Terms & Conditions below.

PRINT SAVINGS
CARD NOW
NEXT: Dosing
Indications

Welchol is indicated as an adjunct to diet and exercise to:

  • reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia
  • reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH)
  • improve glycemic control in adults with type 2 diabetes mellitus
Limitations of Use
  • Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
  • The effect of Welchol on cardiovascular morbidity and mortality has not been determined.
  • Welchol has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase-4 inhibitor
  • Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias
  • Welchol has not been studied in children younger than 10 years of age or in premenarchal girls
Savings Card Offer: Eligibility Criteria and Terms & Conditions

To the Patient: You must present this card to the pharmacist along with your WELCHOL® (colesevelam HCl) prescription to participate in the program. For patients with commercial insurance, savings per prescription of WELCHOL will apply after the following out‐of‐pocket expenses are met: $10 per prescription for a 30‐day supply of WELCHOL or $0 per prescription for a 90‐day supply of WELCHOL. Offer may not be combined with any other program offer or discount for WELCHOL. Savings for WELCHOL are subject to a maximum benefit of $150 per 30‐day prescription or $450 per 90‐day prescription. If you have questions regarding your eligibility or benefits, or wish to discontinue participation, call (877) 264‐2440
(8 AM – 8 PM ET, Monday‐Friday)
. When you use this card, you are certifying that you understand the program rules, regulations, and terms and conditions. You are not eligible if you are enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS; or where taxed, restricted, or prohibited by law; or if you do not otherwise comply with the terms of this card. Further, you agree to discontinue using the card if you enroll in any state or federal health care program during the program period. Offer valid in US and Puerto Rico only.

To the Pharmacist: When you use this card, you are certifying that the patient is not enrolled in any federal, state, or other governmental programs for this prescription.

  • Submit transaction to McKesson Corporation, using BIN #610524.
  • If primary coverage exists, input card information as secondary coverage and transmit using the COB segment of NCPDP transaction. Applicable discounts will be displayed in the transaction response.
  • Acceptance of this card is subject to LoyaltyScript® program Terms and Conditions posted at www.mckesson.com/mprstnc.
  • Patient not eligible if enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS, or where taxed, restricted, or prohibited by law. Offer valid in US and Puerto Rico only.
  • The LoyaltyScript® card is not valid for use with any other prescription drug discount or cash cards for WELCHOL. Claims submitted utilizing the program are subject to audit or validation.
  • LoyaltyScript® is not an insurance card.

Cosette Pharmaceuticals, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.

Trademarks not owned by Cosette Pharmaceuticals, Inc., are property of their respective owners.